The Journal of infectious diseases · 2007
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.
Клиническое исследованиеКлиническое исследование IV фазыСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bhattacharya Sujit Kumar, Sinha Prabhat Kumar, Sundar Shyam, Thakur Chandreshar Prasad, Jha Tara Kant, Pandey Krishna, Das Vidyanand Rabi, Kumar Naveen, Lal Chandrasekhar, Verma Neena, Singh Vijay Pratap, Ranjan Alok, Verma Rakesh Bihari, Anders Gerlind, Sindermann Herbert, Ganguly Nirmal Kumar
Аннотация
BACKGROUND: Visceral leishmaniasis (VL) is a major public health problem in Bihar, accounting for 90% of all cases in India. Development of high levels of resistance to various existing drugs necessitated the search for alternative orally administered drugs. Hospital-based studies have shown that oral miltefosine is a highly effective treatment for VL both in adults and in children.
METHODS: An open, single-arm trial was designed to investigate the feasibility of treatment of VL patients with miltefosine in field conditions in 13 centers in Bihar.
RESULTS: The phase 4 study was conducted among 1132 adult and pediatric VL patients. Compliance was good, with 1084 (95.5%) patients completing the full 28-day treatment course. Nine hundred and seventy-one (85.8%) patients returned for the final cure assessment at 6 months after treatment. The final cure rate was 82% by intention to treat analysis and 95% by per protocol analysis (similar to the 94% cure rate in hospitalized patients). Treatment-related adverse events of common toxicity criteria grade 3 occurred in ~3% of patients, including gastrointestinal toxicity and rise in aspertate amino transferase, alanine amino transferase, or serum creatinine levels, similar to previous clinical experience.
CONCLUSION: This study supports the use of miltefosine in an outpatient setting in an area where VL is endemic.
METHODS: An open, single-arm trial was designed to investigate the feasibility of treatment of VL patients with miltefosine in field conditions in 13 centers in Bihar.
RESULTS: The phase 4 study was conducted among 1132 adult and pediatric VL patients. Compliance was good, with 1084 (95.5%) patients completing the full 28-day treatment course. Nine hundred and seventy-one (85.8%) patients returned for the final cure assessment at 6 months after treatment. The final cure rate was 82% by intention to treat analysis and 95% by per protocol analysis (similar to the 94% cure rate in hospitalized patients). Treatment-related adverse events of common toxicity criteria grade 3 occurred in ~3% of patients, including gastrointestinal toxicity and rise in aspertate amino transferase, alanine amino transferase, or serum creatinine levels, similar to previous clinical experience.
CONCLUSION: This study supports the use of miltefosine in an outpatient setting in an area where VL is endemic.
Предметные рубрики MeSH
Administration, OralAdolescentAdultAgedAlanine TransaminaseAntiprotozoal AgentsAspartate AminotransferasesCapsulesChemical and Drug Induced Liver InjuryChildChild, PreschoolCreatinineDrug Administration ScheduleFemaleGastrointestinal DiseasesHumansIndiaLeishmaniasis, VisceralLiver DiseasesMaleMiddle AgedPatient CompliancePhosphorylcholineTreatment Outcome